Global Cancer Diagnostics Platform Announced

Global Cancer Diagnostics Platform Announced

Big Pharma is racing to find a cure for all types of cancer. Now there’s a $2.8 billion deal that unites two cancer diagnostics companies. Exact Sciences Corporation (NYSE: EXAS), a molecular diagnostics company and maker of the Cologuard colorectal screening test, announced its acquisition of Genomic Health, Inc. (NASDAQ: GHDX) in late July. Genomic Health provides genomic-based diagnostic tests that improve cancer care, including addressing the overtreatment of the disease. Its lead product, Oncotype DX, manages clinical and genomic big data to support research and treatment for over 1 million cancer patients. The combined company will offer two of the strongest brands in cancer... Read More »